ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity

Resistances to immunotherapies remains a major hurdle towards a cure for melanoma in numerous patients. An increase in the mesenchymal phenotype and a loss of differentiation have been clearly associated with resistance to targeted therapies. Similar phenotypes have been more recently also linked to...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheli, Yann, Tulic, Meri K., El Hachem, Najla, Nottet, Nicolas, Jacquel, Arnaud, Gesson, Maeva, Strub, Thomas, Bille, Karine, Picard-Gauci, Alexandra, Montaudié, Henri, Beranger, Guillaume E., Passeron, Thierry, Close, Pierre, Bertolotto, Corine, Ballotti, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789764/
https://www.ncbi.nlm.nih.gov/pubmed/33413419
http://dx.doi.org/10.1186/s12943-020-01306-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789764/
https://www.ncbi.nlm.nih.gov/pubmed/33413419
http://dx.doi.org/10.1186/s12943-020-01306-2

Ejemplares similares